Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal
Pfizer China To Also Offload Manufacturing Site In Hangzhou
Mar 18 2021
•
By
Dean Rudge
The agreement for the biologics site in Hangzhou is expected to close in the first half of 2021 • Source: Shutterstock
More from Biosimilars
More from Products